VISCHER is advising Noema Pharma in this transaction. The team is led by Matthias Staehelin (Corporate, pictured left). Walder Wyss advised Gilde Healthcare Partners, Polaris Partners, Invus Capital and BioMedInvest as investors. The team included
Tags :Walder Wyss
Walder Wyss represented OTTO'S in this legal dispute. The team included Michael Isler (Partner, IP/IT - pictured) and Christine Leuch (Managing Associate, IP/IT).
Helvetica Property Investors has appointed Theodor Härtsch, an experienced lawyer specialized in banking and financial market law, capital market transactions and compliance, to the Board of Directors.
The team comprises Florian Gunz Niedermann (Partner, Corporate/M&A - pictured) and Christian Lütolf (Managing Associate, Corporate/M&A). The Walder Wyss team already advised GetYourGuide in May 2019 in its series E financing
Walder Wyss advised the Fundamenta Group and the sellers on all legal aspects of this transaction. The team included Urs Schenker (Counsel, Corporate/M&A - pictured), Thiemo Sturny (Partner, Corporate/M&A) and Florian
The team included Alexander Gutmans (Partner, Corporate/M&A and Venture Capital - pictured), Robert von Rosen (Partner, Corporate/M&A and Venture Capital) and Karina Tschon (Associate, Corporate/M&A and Venture Capital).
The team was led by Hubertus Hillerström (Partner, Banking & Finance - pictured) and further included Valentine Schnyder (Associate, Banking & Finance), Camille Tistounet (Trainee, Banking & Finance) and Ken Savioz (Trainee, Banking & Finance).
Latham & Watkins and Walder Wyss acted as legal advisors to GetYourGuide in this transaction.
Walder Wyss advised TMH as Swiss legal counsel on the transaction. The team was led by Florian Gunz Niedermann (Partner, Corporate/M&A) and Fabienne Anner (Managing Associate, Corporate/M&A) and further included Timon
Homburger advises VectivBio on USD 110 m crossover financing.The team was led by partner Andreas Müller (pictured left). Walder Wyss advised BPI France, Cowen Healthcare Investments, Novo Ventures, OrbiMed and Versant Ventures as lead
